Tag Archives: blood-based biomarkers

The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor ...

ANGLE plc, the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European consortium to validate blood-based biomarkers for cancer. CANCER-ID is a European consortium funded by the Innovative Medicines Initiative (IMI), with ...